

**CALL FOR  
ABSTRACT**



65<sup>th</sup> Annual Meeting  
Society of Thrombosis and  
Hemostasis Research

**Across Borders**

**22 – 26 February 2021**  
simply online

**Interdisciplinarity in Thrombosis and Hemostasis**

Anesthesiology | Angiology | Cardiology |  
Gynecology/Obstetrics | Hemato-oncology |  
Hepatology/Gastroenterology | Laboratory medicine |  
Neurology | Pediatrics | Transfusion medicine

[www.gth2021.org](http://www.gth2021.org)



**Across  
Borders** | 65<sup>th</sup> Annual Meeting  
Society of Thrombosis and Hemostasis Research  
GTH 2021 | 22 – 26 February  
simply online

## BIENVENUE...

...to the 65<sup>th</sup> Annual Meeting of the Society of Thrombosis and Hemostasis Research. First online!

### ACROSS (NEW) BORDERS

For the first time in its history, the GTH congress was scheduled to be held in the French-speaking part of Switzerland: "La Romandie".

I really hoped that this attractive location would have enabled participants from all Switzerland, Germany and Austria, France and Italy, and possibly from other European countries to gather in Lausanne for four days of science and clinical practice in hemostasis.

The tiny SARS-CoV-2 changed our big plans. Because of the ongoing COVID-19 pandemic, we were considering a hybrid meeting, but we had eventually to opt for an exclusively online congress. Although this choice will cause some burning loss, it will open new opportunities as well.

We will miss the wonderful surroundings of Lausanne with its vineyards, the mountains, and the lake. We will miss the encounters and lively discussions. We will miss friends and colleagues.

However, we will profit from the digital network. Possibly, the online congress will attract curious minds who would not have attended a face-to-face GTH congress, thus widening our audience. For Abstracts and Oral Communications, online discussion forums will allow interacting with the authors during the whole congress. The lively 3D industrial exhibition will be accessible for a whole month. The online congress format will solve the problem of choosing between parallel sessions: all presentations will be available online so that you will be able to listen to them at your best convenience. You could even organize a "beer & pizza workshop", enjoying your preferred talks with your team ... Just think **ACROSS BORDERS** and let us make the best out of the situation!

### ACROSS (OLD) BORDERS

Hemostasis is just fascinating! In my experience, one of the several reasons is its interdisciplinary character, which we realize daily discussing clinical cases with colleagues from other medical specialties: in emergency rooms and operating theatres, on pediatric wards, in the lab and in clinics as diverse as hepatology, obstetrics, or hematology.

The 2021 GTH congress will focus on interdisciplinary aspects of hemostasis, opening the doors to colleagues from other medical fields, and opening the minds towards different points of view and ways of thinking hemostasis.

### ACROSS BORDERS

We have a privileged profession! Daily, we meet human beings in quite vulnerable phases of their lives – this is our greatest responsibility. Doing research, we can create knowledge – this is our greatest challenge.

Clinical passion and research! My first medical teacher, Carlofelice Beretta-Piccoli (1946-1994) used to say to us young residents and exemplified through his own professional life that an accomplished physician is intellectually curious, scientifically accurate and able to "appassionarsi al destino del paziente".

The motto of the 65<sup>th</sup> Annual Meeting of the Society of Thrombosis and Hemostasis Research – **ACROSS BORDERS** – stands for all of this: Internationality, Interdisciplinary Hemostasis, Science and Humanity... and the digital barrier.

We – the local, Swiss and international organizing committees – have been working for setting up the frame conditions for a successful scientific congress.

However, only if you will submit your best research abstracts and actively participate, the congress will become "enriching and memorable"... even if simply online!

Bienvenue

### Lorenzo Alberio

Médecin chef  
Centre Hospitalier Universitaire Vaudois  
Service et Laboratoire central d'hématologie  
Rue du Bugnon 46  
CH-1011 Lausanne  
lorenzo.alberio@chuv.ch

## GENERAL INFORMATION

### Official language

English (no simultaneous translations)

### Congress organizer

Meister ConCept GmbH  
Bahnhofstrasse 55  
CH-5001 Aarau  
P +41 62 836 20 90  
gth2021@meister-concept.ch  
www.meister-concept.ch

## REGISTRATION

Online from July 1<sup>st</sup> 2020 under [www.gth2021.org](http://www.gth2021.org)

### Registration fee

#### Early Bird until December 31<sup>st</sup> 2020

GTH Member	CHF 165.00
GTH Non-Member	CHF 210.00
PhD student*, MTA, nursing staff, physician in training*, retired member	CHF 85.00
Student*	CHF 30.00

#### Late fees from January 1<sup>st</sup> 2021

GTH Member	CHF 200.00
GTH Non-Member	CHF 245.00
PhD student*, MTA, nursing staff, physician in training*, retired member	CHF 100.00
Student*	CHF 40.00

*\*Proof of current status needs to be sent to the Congress organizer by mail. Only then a deduction can be granted.*

### Payment

The request for payment by credit card or bank transfer will be done directly by the system. A confirmation/invoice will be automatically sent to the registered e-mail address.

### Account information

Aargauische Kantonalbank  
Bahnhofplatz 1, 5001 Aarau  
IBAN:  
CH88 0076 1136 8938 5203 3  
BIC (SWIFT): KBAGCH22  
Account holder: GTH 2021

## ORGANIZING COMMITTEES

### Congress President

Lorenzo Alberio, Lausanne (CH)

### Local Organizing Committee

Alessandro Aliotta, Lausanne (CH)

Debora Bertaggia Calderara, Lausanne (CH)

Maxime Zermatten, Lausanne (CH)

### National Organizing Committee

Alessandro Casini, Geneva (CH)

Giuseppe Colucci, Lugano (CH)

Pierre Fontana, Geneva (CH)

Lukas Graf, St. Gallen (CH)

Inga Hegemann, Zurich (CH)

Christian Heinis, Lausanne (CH)

Johanna Kremer, Bern (CH)

Thomas Lecompte, Geneva (CH)

Maria Martinez, Basel (CH)

Michael Nagler, Bern (CH)

Emanuelle Scala, Lausanne (CH)

Verena Schröder, Bern (CH)

Jan-Dirk Studt, Zurich (CH)

### International Organizing Committee

Marie-Christine Alessi, Marseille (FR)

Cihan Ay, Wien (AT)

Marco Cattaneo, Milano (IT)

Yves Gruel, Tours (FR)

Bettina Kemkes-Matthes, Giessen (DE)

Christoph Male, Wien (AT)

Pierre Mangin, Strasbourg (FR)

Christine Mannhalter, Wien (AT)

Patrizia Noris, Pavia (IT)

Alessandro Pecci, Pavia (IT)

Ulrich Sachs, Giessen (DE)

Barbara Zieger, Freiburg (DE)

### Theme Leaders

#### Anesthesiology

Gabriele Casso, Lugano (CH)

Carlos Marcucci, Lausanne (CH)

#### Angiology

Lucia Mazzolai, Lausanne (CH)

Marc Righini, Geneva (CH)

#### Cardiology

Tobias Rutz, Lausanne (CH)

Marco Valgimigli, Bern (CH)

#### Gynecology/Obstetrics

David Baud, Lausanne (CH)

Daniel Surbek, Bern (CH)

#### Hemato-oncology

Bernhard Gerber, Bellinzona (CH)

Walter Wuillemin, Luzern (CH)

#### Hepatology

Andrea De Gottardi, Lugano (CH)

Guido Stirnimann, Bern (CH)

#### Laboratory medicine

Wolfgang Korte, St. Gallen (CH)

Dimitrios Tsakiris, Basel (CH)

#### Lab technicians

Evelyne Giabbani, Zurich (CH)

Anita Gähler, Luzern (CH)

Silvio Kathriner, Luzern (CH)

#### Neurology

Urs Fischer, Bern (CH)

Patrik Michel, Lausanne (CH)

#### Pediatrics

Manuela Albisetti, Zurich (CH)

Mattia Rizzi, Lausanne (CH)

#### Transfusion medicine

Michel Prudent, Lausanne (CH)

Sacha Zeerleder, Bern (CH)

## ABSTRACT SUBMISSION

Online from July 1<sup>st</sup> 2020 until October 11<sup>th</sup> 2020 under [www.gth2021.org](http://www.gth2021.org)

### Abstract topics

#### Subject area

- Acquired bleeding disorders
- Antithrombotic treatment
- Arterial thromboembolism
- Coagulation and fibrinolysis
- COVID-19
- Crosstalks between hemostasis and other systems
- Diagnostics and laboratory tests
- Hereditary bleeding disorders
- In vitro and in vivo models of hemostasis
- Innovation and Novelties
- Platelets - Disorders of platelet function and numbers
- Platelets - Physiology
- Vascular wall biology and disorders
- Venous thromboembolism
- von Willebrand factor and ADAMTS13
- Miscellaneous

#### Interdisciplinary area

- Anesthesiology
- Angiology
- Basic research
- Cardiology
- Clinical practice
- Clinical research
- Gynecology/Obstetrics
- Hemato-oncology
- Hepatology/Gastroenterology
- Intensive care
- Laboratory medicine
- Laboratory technology
- Neurology
- Pediatrics
- Transfusion medicine
- Trauma/Surgery

Each abstract will be tagged with one subject area and up to three interdisciplinary area

### Digital poster exhibition

There will be no physical poster exhibition. All accepted posters will be presented digitally and with the possibility to be called up on screens. In addition to this, the posters will be kept in a virtual library on the congress website after the congress.


## MAIN CONGRESS TOPICS & SESSION FORMATS

### Main topics

The focus of the 2021 GTH congress will be on **interdisciplinary aspects of hemostasis and thrombosis**, with scientific presentations on research and clinical practice in *anesthesiology, angiology, cardiology, gynecology/obstetrics, hemato-oncology, hepatology, laboratory medicine, neurology, pediatrics* and *transfusion medicine*.

### Session formats

- Plenary Lectures
- State of the Art
- Oral Communications
- Satellite Symposia
- Digital poster presentation



# Give a fresh perspective on life, with ELOCTA®



Swedish Orphan Biovitrum AG,  
Winkelriedstrasse 35, 6003 Luzern, [www.sobiswiss.ch](http://www.sobiswiss.ch)

Elocta® ist indiziert für die Behandlung und Prophylaxe von Blutungen bei vorbehandelten Patienten mit Hämophilie A (kongenitaler Faktor-VIII-Mangel).

**Elocta® (Efmorotocog alfa). I:** Behandlung und Prophylaxe von Blutungen bei vorbehandelten Patienten mit Hämophilie A (kongenitaler Faktor-VIII-Mangel). **D:** Intravenöse Anwendung nach Rekonstitution. Berechnung der Dosis in Abhängigkeit von Körpergewicht und den zu erreichenden Faktor-VIII-Spiegeln. Empfohlene Faktor-VIII-Spiegel Hämarthrose im Frühstadium, Muskelblutung oder orale Blutung 20–40 I.E./dl; umfangreichere Hämarthrose, Muskelblutung oder Hämatom 30–60 I.E./dl; lebensbedrohende Blutungen 60–100 I.E./dl; kleinere chirurgische Eingriffe 30–60 I.E./dl; grössere chirurgische Eingriffe 80–100 I.E./dl. Individualisierte Langzeitprophylaxe 50 I.E./kg alle 3–5 Tage. Therapieüberwachung empfohlen. **KI:** Überempfindlichkeit gegenüber Wirkstoff oder Hilfsstoffen. **W/VM:** Überempfindlichkeitsreaktionen oder allergische Reaktionen, Bildung neutralisierender Antikörper. **IA:** Keine bekannt. **UW.:** Gelegentlich Faktor-VIII-Inhibition (PTP), Kopfschmerzen, Schwindel, Dysgeusie, Bradykardie, Hypertonie, Hitzewallungen, Angiopathie, Husten, Unterbauchschmerzen, Ausschlag, Arthralgie, Myalgie, Rückenschmerzen, Gelenkschwellung, Unwohlsein, Schmerzen im Brustraum, Kältegefühl, Hitzegefühl, Hypotonie im Rahmen des Eingriffs. Selten allergische Überempfindlichkeitsreaktionen bis hin zum anaphylaktischen Schock. Bei unzureichendem klinischen Ansprechen aufgrund Bildung neutralisierender Antikörper gegen Faktor VIII, ein spezialisiertes Hämophiliezentrum kontaktieren. **P:** Pulver und Lösungsmittel zur Herstellung einer Injektionslösung. Packung enthält 1 Durchstechflasche mit Pulver, 3ml Lösungsmittel in einer Fertigspritze, 1 Kolbenstange, 1 Adapter für die Durchstechflasche, 1 Infusionsset, 2 Alkoholtupfer, 2 Pflaster, 1 Mullkompressen. Verkaufskategorie B. **Stand:** August 2019. **Zul.-Inh.:** Swedish Orphan Biovitrum AG, Luzern. Ausführliche Informationen: Arzneimittel-Fachinformation unter [www.swissmedinfo.ch](http://www.swissmedinfo.ch).

Elocta® und Sobi sind Marken von Swedish Orphan Biovitrum AB (publ).  
© 2020 Swedish Orphan Biovitrum AB (publ). Alle Rechte vorbehalten.